InDex Pharmaceuticals Holding AB announced that the positive results from their pharmacokinetic (PK) study with cobitolimod, targeting patients with moderate to severe ulcerative colitis, will be showcased at the United European Gastroenterology Week (UEGW). This abstract was distinguished as one of the best for poster presentation and will also be orally presented in a moderated session.
Jenny Sundqvist, CEO of InDex Pharmaceuticals, expressed her satisfaction with the selection, emphasizing the medical community’s keen interest in their findings. The study’s results, presented by Professor Per Hellström, revealed limited systemic uptake of cobitolimod and a promising response rate among patients. InDex Pharmaceuticals will also have a presence at UEGW, providing further information about cobitolimod and their ongoing phase III program, CONCLUDE.